#South Korea #Seoul #CNT201 #Connext #Dupuytren's Contracture

Connext's Advancement in Clinical Trials

Connext, a therapeutics company specializing in innovative treatments for unmet medical needs, has reached a significant milestone by completing the enrollment process for its Phase 2 clinical trial of CNT201 aimed at treating Dupuytren's contracture. The enrollment was finalized approximately five months after the first patient received treatment, showcasing Connext's efficient trial execution.

The clinical trial is part of a broader study initiated in 2024 after the U.S. Food and Drug Administration (FDA) granted clearance for Connext's investigational new drug application. The first phase of the trial confirmed the safety and tolerability of CNT201, paving the way for the second phase which began in February 2026. The current Phase 2 trial is organized as a randomized, double-blind, placebo-controlled study, which is designed to rigorously evaluate the efficacy and safety of CNT201.

Study Details and Implementation

In total, 56 participants are enrolled, divided into two dose groups of 24 each, while eight participants are assigned to a placebo group. Participants will receive the treatment at intervals of four weeks and may continue for up to three doses depending on their treatment response. This structured approach allows for comprehensive follow-up assessments aimed at evaluating both the durability of responses and overall safety.

The primary focus of the CNT201 trial is Dupuytren's contracture, a disorder that leads to the formation of thickened connective tissue in the palm, causing one or more fingers to bend towards the palm. This condition affects hand function and can significantly impact the quality of life. If the trial yields positive outcomes, it will not only support CNT201 as a treatment option for Dupuytren's contracture but may also provide a platform for future development in other conditions.

Potential Future Applications

There are exciting prospects beyond Dupuytren's contracture for CNT201. Should the current trial demonstrate the treatment's efficacy and safety, Connext plans to explore expansion opportunities into treating Peyronie's disease and cellulite. Both conditions, which involve fibrous tissue abnormalities, currently have limited treatment alternatives, creating potential avenues for innovative injectable therapies.

Peyronie's disease can cause abnormal curvature of the penis due to plaque formation, while cellulite manifests as dimpled skin caused by fibrous bands beneath the skin’s surface. Connext believes that CNT201 could fill a crucial gap in therapeutic options for these conditions as well.

Looking Ahead

To capitalize on the potential efficacy of CNT201 in these new indications, Connext intends to submit separate Phase 2a investigational new drug applications to the FDA, targeting Peyronie's disease and cellulite in 2026. This strategy aims to mitigate development risks associated with launching new treatments.

Chief Executive Officer of Connext, Woo Jong Lee, emphasized the importance of this milestone, stating, "Completing enrollment in the Phase 2 portion of the CNT201 trial within approximately five months of first patient dosing marks an important clinical milestone for Connext. With topline data expected in late 2026, we believe CNT201 has the potential to become a meaningful treatment option for patients with Dupuytren's contracture and to serve as a platform for additional collagenase-based development opportunities in Peyronie's disease and cellulite."

Connext continues to show promise in the therapeutic landscape, focusing on addressing significant unmet medical needs with its innovative approach and dedication to developing effective treatment options.